IMTX
Closed
Immatics Nv
5.54
+0.16 (+2.97%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.38
Day's Range: 5.2701 - 5.64
Send
sign up or login to leave a comment!
When Written:
6.92
Immatics NV is a clinical-stage biopharmaceutical company that is focused on developing and commercializing immunotherapies for the treatment of cancer. The company is based in Tübingen, Germany and Houston, Texas, USA.
Immatics NV is developing a range of immunotherapies that are designed to harness the power of the immune system to fight cancer. The company's lead product candidate is IMA201, which is a T-cell receptor (TCR) based immunotherapy that is being developed for the treatment of solid tumors.
The company's technology platform is based on the identification of cancer-specific peptides that are presented on the surface of tumor cells. Immatics NV uses this information to develop TCR-based immunotherapies that are designed to target these peptides and activate the immune system to attack the cancer cells.
Immatics NV was founded in 2000 and has raised over $200 million in funding to date. The company is backed by a number of high-profile investors, including Amgen, AT Impf GmbH, and MIG Verwaltungs AG.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Immatics NV is developing a range of immunotherapies that are designed to harness the power of the immune system to fight cancer. The company's lead product candidate is IMA201, which is a T-cell receptor (TCR) based immunotherapy that is being developed for the treatment of solid tumors.
The company's technology platform is based on the identification of cancer-specific peptides that are presented on the surface of tumor cells. Immatics NV uses this information to develop TCR-based immunotherapies that are designed to target these peptides and activate the immune system to attack the cancer cells.
Immatics NV was founded in 2000 and has raised over $200 million in funding to date. The company is backed by a number of high-profile investors, including Amgen, AT Impf GmbH, and MIG Verwaltungs AG.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!